In comparison to IDHmut gliomas, IDHwt gliomas have greater activation of receptor tyrosine kinase signaling through EGFR gain, MET gain, and BRAF gain, in addition to increased gains in cell cycle activators and losses of cell cycle inhibitors compared to IDHmut gliomas. This evidence concerns the gene BRAF and central nervous system cancer.